Sign in

You're signed outSign in or to get full access.

Ethan Nadelmann

Director at Green Thumb Industries
Board

About Ethan Nadelmann

Ethan Nadelmann, 68, has served as an independent director of Green Thumb Industries (GTBIF) since April 2023 and resides in New York, USA . He is a long-time drug policy expert: founder and former executive director of the Drug Policy Alliance (2000–2017), previously led The Lindesmith Center (1994–2000), and was a politics and public affairs professor at Princeton University (1987–1994) . He hosts and executive produces the PSYCHOACTIVE podcast and holds a BA, JD, and PhD from Harvard University and a master’s in international relations from the London School of Economics .

Past Roles

OrganizationRoleTenureCommittees/Impact
Princeton UniversityProfessor of politics and public affairs1987–1994Academic leadership and policy scholarship
The Lindesmith Center (Open Society Institute project)Director1994–2000Led drug policy research and advocacy
Drug Policy AllianceFounder; Executive Director2000–2017Oversaw ballot initiatives and legislative efforts on cannabis legalization

External Roles

OrganizationRoleTenureCommittees/Impact
PSYCHOACTIVE podcastFounder, host, executive producerCurrentPublic discourse on cannabis and drug policy
Open Society Foundations – International Harm Reduction DevelopmentCo-founder; Advisory board memberVarious periodsStrategy and harm reduction advocacy
OSF Global Drug Policy ProgramAdvisory board memberVarious periodsGlobal drug policy guidance

Board Governance

  • Committee assignments: Compensation Committee member (committee currently chaired by Jeffrey Goldman; other members Hannah Ross) .
  • Independence: The Board determined Mr. Nadelmann is independent under NYSE and Canadian rules (one of four independent directors) .
  • Attendance and engagement: In 2024 the Board held six meetings; all directors attended at least 75% of applicable Board and committee meetings; all current directors attended the 2024 AGM .
  • Years of service on this board: Director since 2023 .
  • Board leadership context: CEO also serves as Chair; Board periodically reviews leadership structure .

Fixed Compensation

Director compensation program (effective December 1, 2022):

ComponentAnnual AmountNotes
Cash retainer$75,000Paid quarterly
Equity (RSUs)$175,000Fully vested RSUs, paid quarterly

Mr. Nadelmann’s 2024 director compensation:

NameFees Earned (Cash)Stock Awards (RSUs)Total
Ethan Nadelmann$75,000 $175,000 $250,000

Quarterly RSU grant-date fair values:

QuarterRSU Fair Value
March 1, 2024$43,750
June 1, 2024$43,750
September 1, 2024$43,750
December 1, 2024$43,750

Performance Compensation

ItemDetail
Performance conditions tied to director payNone disclosed; director RSUs are fully vested upon grant and not subject to performance metrics

Other Directorships & Interlocks

ItemDetail
Current public company boardsNone; “None of our directors are presently directors of any other reporting issuer.”
Compensation committee interlocksNo interlocks for Mr. Nadelmann; committee members in 2024 were Berger (through June 12, 2024), Goldman (chair from June 12, 2024), Nadelmann, Ross; related party relationships noted for Wendy Berger (leases) and Goldman’s prior consulting ended in 2022

Expertise & Qualifications

  • Cannabis industry and drug policy expertise; extensive advocacy leadership and public policy credentials .
  • Operating and management experience from leading non-profit organizations and initiatives .
  • The Board’s skills matrix flags him for independence, cannabis industry expertise, operating/management experience, CEO experience, and community/social impact; he is not flagged for finance/accounting expertise .

Equity Ownership

HolderSubordinate Voting Shares Beneficially Owned% of Total Capital StockVoting %Options/RSUs/Warrants within 60 days
Ethan Nadelmann36,434 <1% (*) <1% (*) None reported (no options/RSUs/warrants within 60 days)
  • Insider trading policy prohibits short selling and hedging by insiders (which include directors) .
  • No indebtedness to the company and no company-guaranteed loans to directors reported for 2024 .
  • Related party transactions disclosed involve other directors/executives; none involve Mr. Nadelmann .

Governance Assessment

  • Strengths

    • Independence and attendance: Independent director with at least 75% meeting attendance in 2024; attended AGM .
    • Relevant domain expertise: Deep cannabis policy and advocacy background, aligning board oversight with GTI’s regulatory environment .
    • Pay structure and alignment: Modest cash retainer complemented by fully vested RSUs; 2024 total $250k, consistent with program .
    • Ownership: Direct beneficial ownership of 36,434 shares, providing some alignment; no options/warrants within 60 days; policy prohibits hedging .
    • Oversight roles: Active on Compensation Committee; Board has related-party transaction review through the Audit Committee and a formal policy .
  • Watch items / potential risks

    • Skills coverage: Not flagged for finance/accounting expertise in the Board matrix; he serves on the Compensation Committee where market benchmarking and pay governance are critical .
    • External consultants: The Compensation Committee did not use an external compensation consultant or formal benchmarking in 2024, increasing reliance on internal judgment amid a complex sector .
    • Board leadership: Combined CEO/Chair structure places greater importance on independent director oversight; continued monitoring of independent governance practices is warranted .
    • Dual-class voting structure: Company-wide governance consideration (not specific to Nadelmann) with Super and Multiple Voting Shares affecting voting power distribution .
  • Red flags

    • None identified specific to Mr. Nadelmann: no related-party transactions, no indebtedness, and compliance with insider trading restrictions noted .

Clawback: All awards under the Stock and Incentive Plan (including director RSUs) are subject to clawback pursuant to company policy and applicable law .